+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Esophageal Cancer Drug Pipeline Analysis Report 2025- Product Image
Esophageal Cancer Drug Pipeline Analysis Report 2025- Product Image
New

Esophageal Cancer Drug Pipeline Analysis Report 2025

  • PDF Icon

    Drug Pipelines

  • 200 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 6102802
Description Jump to:
The GLOBOCAN database revealed that there were 544,100 esophageal cancer deaths and 604,100 new cases worldwide in 2020, translating to age-standardized incidence and mortality rates of 6.3 and 5.6 per 100,000, respectively. Interestingly, men account for about 70% of instances, and there is a significant gender disparity in frequency worldwide, with men being impacted two to five times more frequently than women.

Report Coverage

The Esophageal Cancer Drug Pipeline Report by the publisher gives comprehensive insights into the drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for esophageal cancer. The report includes the analysis of over 50 pipeline drugs and 15+ companies . The esophageal cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from esophageal cancer. The detailed analysis of each drug, drug class, clinical studies, phase type, molecule type, route of administration and ongoing product development activities related to esophageal cancer are covered. Moreover, esophageal cancer collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.

Esophageal Cancer Drug Pipeline Outlook

Esophageal cancer develops at the esophagus, the lengthy tube that connects the throat to the stomach. It can spread to other areas of the body and usually begins in the cells that line the esophagus. The common categories of the disease include squamous cell carcinoma and adenocarcinoma. This cancer is more common in men (particularly those aged above 50) and people with a history of alcohol or tobacco use. Patients suffering from the condition may experience symptoms like chest pain, trouble swallowing, and inexplicable weight loss. Esophageal cancer treatment is more difficult because it is frequently discovered at an advanced stage.

The patient's health, the disease's location, and its stage all affect how esophageal cancer is treated. Endoscopic techniques can be used to remove tiny tumors in early-stage malignancies. Localized cancer frequently results in surgery, such as an esophagectomy, which involves removing all or part of the esophagus. Before or after surgery, chemotherapy and radiation therapy are frequently utilized to reduce tumor size or eradicate any cancer cells that may still be present. Chemotherapy, radiation, and targeted treatments like immunotherapy may be used in conjunction to treat advanced-stage cancer to control symptoms and extend survival. Regular follow-ups are required for monitoring after treatment. A large number of clinical trials for esophageal cancer has influenced the pipeline landscape positively.

Esophageal Cancer - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of esophageal cancer drug candidates based on several segmentations including:

By Phase

  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

By Molecule Type

  • Oligonucleotide
  • Peptide
  • Small Molecule

By Route of Administration

  • Oral
  • Parenteral
  • Others

Esophageal Cancer - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase I covers a major share of the total clinical trials for esophageal cancer with 38 pipeline drugs in phase I.

Esophageal Cancer - Pipeline Assessment Segmentation, By Molecule Type

The drug molecule categories covered under esophageal cancer pipeline report include oligonucleotides, peptides and small molecules. Studies reveal that targeted monoclonal antibodies have been highly effective in the management of esophageal cancer. The esophageal cancer report provides a comparative analysis of the molecule type for each molecule in various phases of clinical trials for esophageal cancer.

Esophageal Cancer Clinical Trials Assessment - Competitive Dynamics

The report for the esophageal cancer drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed esophageal cancer therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in esophageal cancer clinical trials:
  • F. Hoffmann-La Roche
  • Merck Sharp & Dohme LLC
  • Novartis Pharmaceuticals
  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Jazz Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Ono Pharmaceutical Co. Ltd
  • Jiangsu HengRui Medicine Co., Ltd.
  • CellSeed Inc.
  • PhytoHealth Corporation
  • BeiGene, Ltd.

Esophageal Cancer - Emerging Drugs Profile

Major drugs currently in the drug pipeline are as follows:

Drug: Pembrolizumab

The trial studies the safety and efficacy of Pembrolizumab in patient suffering from esophageal cancer. The trial is sponsored by Merck Sharp & Dohme LLC and is currently under phase II.

Drug: Lomvastomig

The study evaluates the efficacy and safety of lomvastomig for esophageal cancer treatment. The trial is sponsored by F. Hoffmann-La Roche and is currently under phase II.

Drug: Lapatinib

The trial, sponsored by Novartis Pharmaceuticals and currently in phase III. It evaluates the efficacy and tolerability of Lapatinib in patients with esophageal cancer.

Reasons To Buy This Report

The Esophageal Cancer Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for esophageal cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into esophageal cancer collaborations, regulatory environments, and potential growth opportunities within the treatment landscape.

Key Questions Answered in the Esophageal Cancer - Pipeline Assessment Report

  • What is the current landscape of esophageal cancer pipeline drugs?
  • Which companies/institutions are developing esophageal cancer therapeutic drugs?
  • How many phase II drugs are currently present in esophageal cancer pipeline drugs?
  • Which company is leading the esophageal cancer pipeline development activities?
  • What is the current esophageal cancer commercial assessment?
  • What are the opportunities and challenges present in the esophageal cancer drug pipeline landscape?
  • What is the efficacy and safety profile of esophageal cancer pipeline drugs?
  • Which companies/institutions are involved in esophageal cancer collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in esophageal cancer?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Esophageal Cancer Pipeline
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Types of Esophageal Cancer
3.5 Diagnosis
3.6 Treatment
4 Patient Profile: Esophageal Cancer Pipeline
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Esophageal Cancer Pipeline: Epidemiology Snapshot
5.1 Esophageal Cancer Pipeline Incidence by Key Markets
5.2 Esophageal Cancer Pipeline - Patients Seeking Treatment in Key Markets
6 Esophageal Cancer Pipeline: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Esophageal Cancer Pipeline: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Esophageal Cancer Pipeline, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 Drug Pipeline Comparative Analysis
9.1 List of Esophageal Cancer Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Esophageal Cancer Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Camrelizumab
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Pembrolizumab
10.2.3 Regorafenib
10.2.4 Nivolumab
10.2.5 Other Drug
11 Esophageal Cancer Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Panitumumab
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 UFT (Tegafur/Uracil)
11.2.3 Durvalumab
11.2.4 Temozolomide
11.2.5 Other Drugs
12 Esophageal Cancer Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Olaparib
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Donafenib Tosilate
12.2.3 Capecitabine (Xeloda)
12.2.4 Other Drugs
13 Esophageal Cancer Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Esophageal Cancer, Key Drug Pipeline Companies
14.1 Jiangsu HengRui Medicine Co., Ltd.
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Ono Pharmaceutical Co. Ltd
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Merck & Co., Inc.
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 CellSeed Inc.
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Jazz Pharmaceuticals, Inc.
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Hoffmann-La Roche Ltd.
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 Bristol-Myers Squibb Company
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region16 Terminated or Suspended Pipeline Products

Related Topics

Related Products

Esophageal Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape - Product Image

Esophageal Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

  • Report
  • 73 Pages
  • Global
From
Esophageal Cancer- Pipeline Insight, 2025 - Product Image

Esophageal Cancer- Pipeline Insight, 2025

  • Clinical Trials
  • 240 Pages
  • Global
From
Esophageal Cancer: Competitive Landscape - Product Image

Esophageal Cancer: Competitive Landscape

  • Report
  • 88 Pages
  • Global
From
Esophageal Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Esophageal Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 137 Pages
  • Global
From
Esophageal Cancer Patient Pool Analysis, Market Size and Market Forecast APAC - 2034 - Product Image

Esophageal Cancer Patient Pool Analysis, Market Size and Market Forecast APAC - 2034

  • Report
  • 120 Pages
  • Asia Pacific
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.